DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Gout Therapeutics Market 2016-2020" report to their offering.
The report forecasts the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The use of regenerative medicine is an emerging treatment option for the treatment of gout. These regenerative medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and thus help in establishing the normal function. The various regenerative techniques include cell therapy, growth factor therapy, and others.
According to the report, introduction of novel urate-lowering agents will drive growth in this market. Urate-lowering agents are increasingly becoming the preferred choice of treatment for gout, which will be used as add-on therapy to the existing standard of care and target the gout patients who failed the previous treatment.
Key vendors:
- AstraZeneca
- Horizon Pharma
- Takeda Pharmaceuticals
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Gout: Disease overview
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Key buying criteria
PART 09: Market segmentation by drug class
PART 10: Market segmentation by type of disease
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Key vendor analysis
PART 19: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/dh5v2d/global_gout